Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

NCT07527806 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab (Herceptin)
DRUG: Pertuzumab
DRUG: Combination product: Trastuzumab + Pertuzumab
DRUG: Docetaxel or Nab-paclitaxel
DRUG: carboplatin
DRUG: CDK4/6 inhibitor
DRUG: Aromatase Inhibitor (AI)
DRUG: ADC

Sponsor

Peking University Cancer Hospital & Institute